Methods

Two surveys were conducted in Germany to evaluate satisfaction among patients on interferon beta-1b (Betaseron®) using BETACONNECT™ (Table 1): Survey 1 was conducted to evaluate overall satisfaction with BETACONNECT™ and the importance of its features; Survey 2 was conducted to further validate the satisfaction levels observed in Survey 1 and gain a deeper understanding of the impact of BETACONNECT™ on the patient’s injection experience.

Results (cont.)

Reasons for Satisfaction with BETACONNECT™

- Unaided, patients in Survey 1 said the primary driver for satisfaction with BETACONNECT™ in Survey 1 (Figure 2) and Survey 2 (Figure 3) were positive
- The majority of patients preferred BETACONNECT™ over their previous autoinjector, felt it was easy to use, and were confident when performing an injection with it.
- Patients were very likely to recommend BETACONNECT™ to a friend.

Survey 1 was supported by Bayer Vital GmbH, Leverkusen, Germany. Survey 2 was supported by Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, United States.

Impact on the Patient Experience

- Participants from Survey 2 largely agreed BETACONNECT™ had a favorable impact on their patient experience, including comfort of injections, ease of handling, the ability to reach injection sites, and reduced anxiety/pain (Figure 7).
- Most patients using the reminder function stated they were less likely to miss an injection, suggesting the autoinjector may increase adherence of patients on interferon beta-1b therapy.

Conclusions

- The results from the two complimentary surveys confirm the preference for BETACONNECT™ as a precise device and suggest BETACONNECT™ may help increase adherence of patients on interferon beta-1b therapy.
- Overall patient satisfaction with the BETACONNECT™ autoinjector was high, driven by its ease of use, reduction of irritation and pain at the injection site, and smoother injections.
- Patients believed the new features of the autoinjector were important and stated that the lights and buttons helped guide the injection process.
- Most users reporting difficulty or concerns with their previous autoinjector preferred BETACONNECT™ and indicated the autoinjector’s unique communication features were important and stated that the lights and buttons helped guide the injection process.
- The device can also transfer the collected data to an optional mobile phone application/computer program and a navigator application to enhance communication between patients and health care professionals and to help patients maintain adherence with therapy.

References


Assessment of Features

- Majority of features were rated as either “very important” or “important” by most patients in their injection experience, including comfort of injections, ease of handling, the ability to reach injection sites, and reduced anxiety/pain (Figure 5). In particular, patients considered the adjustable injection depth and speed, safety release, optical and acoustic signals, and rechargeable battery to be among the most important features (Figure 3).

Satisfaction with BETACONNECT™ among patients using the autoinjector to administer interferon beta-1b

Objectives

- To assess satisfaction with BETACONNECT™ among patients using the autoinjector to administer interferon beta-1b.
- To capture any previous injection method or the hesitancy to start therapy due to previously used autoinjector.

Method

- Two surveys were conducted in Germany to evaluate satisfaction among patients on interferon beta-1b (Betaseron®) using BETACONNECT™ (Table 1): Survey 1 was conducted to evaluate overall satisfaction with BETACONNECT™ and the importance of its features; Survey 2 was conducted to further validate the satisfaction levels observed in Survey 1 and gain a deeper understanding of the impact of BETACONNECT™ on the patient’s injection experience.

Overall Impressions of BETACONNECT™

- Overall impressions of BETACONNECT™ in Survey 1 (Figure 2) and Survey 2 (Figure 3) were positive.
- The majority of patients preferred BETACONNECT™ over their previous autoinjector, felt it was easy to use, and were confident when performing an injection with it.
- Patients were very likely to recommend BETACONNECT™ to a friend.

Overall Impressions of BETACONNECT™ in Survey 1 (n=1365)

Table 1: Design of the 2 surveys

<table>
<thead>
<tr>
<th>Survey 1</th>
<th>Survey 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=1365</td>
<td>N=118</td>
</tr>
<tr>
<td>Participants who used BETACONNECT for &gt;1 year (%)</td>
<td>69.7%</td>
</tr>
<tr>
<td>Participants who had a favorable injection experience (%)</td>
<td>81.9%</td>
</tr>
<tr>
<td>Participants who would recommend BETACONNECT to a friend (%)</td>
<td>93.4%</td>
</tr>
</tbody>
</table>

Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b

Table 2: Comparison of survey responses (Survey 1 vs. Survey 2)

<table>
<thead>
<tr>
<th>Feature</th>
<th>Survey 1</th>
<th>Survey 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comfort of injections</td>
<td>81.9%</td>
<td>83.6%</td>
</tr>
<tr>
<td>Ease of handling</td>
<td>83.6%</td>
<td>85.3%</td>
</tr>
<tr>
<td>Ability to reach injection sites</td>
<td>76.8%</td>
<td>79.8%</td>
</tr>
<tr>
<td>Reduced anxiety/pain</td>
<td>74.4%</td>
<td>77.2%</td>
</tr>
</tbody>
</table>

Survey 1 was supported by Bayer Vital GmbH, Leverkusen, Germany. Survey 2 was supported by Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, United States.

Participants who answered “don’t know” or did not answer were excluded from the tally for that question.